Generalizability of clinical trial results for generalized anxiety disorder to community samples

Depression and Anxiety

Volumn 29, Issue 7, 2012, Pages 614-620

  Hoertel, Nicolas ^a,b   Le Strat, Yann ^a,b   Blanco, Carlos ^c   Lavaud, Pierre ^d   Dubertret, Caroline ^a,b  

^a HÔPITAL LOUIS MOURIER   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d BICÊTRE HOSPITAL   (France)

Author keywords

clinical trials; exclusion criteria; generalizability; generalized anxiety disorder; National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)

Indexed keywords

ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); DSM-IV; GENERALIZED ANXIETY DISORDER; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSYCHOTHERAPY;

ANXIETY DISORDERS; CLINICAL TRIALS AS TOPIC; HEALTH SURVEYS; HUMANS; PATIENT SELECTION; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS; UNITED STATES;

EID: 84863455386     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.21937     Document Type: Article

References (72)

1. Harter MC, Conway KP, Merikangas KR,. Associations between anxiety disorders and physical illness. Eur Arch Psychiatry Clin Neurosci 2003; 253: 313-320. (Pubitemid 38075973)
2. Judd LL, Kessler RC, Paulus MP, et al. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta Psychiatr Scand Suppl 1998; 393: 6-11. (Pubitemid 28428186)
3. Goldenberg IM, White K, Yonkers K, et al. The infrequency of "pure culture" diagnoses among the anxiety disorders. J Clin Psychiatry 1996; 57: 528-533. (Pubitemid 26412505)
4. Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 2005; 35: 1747-1759. (Pubitemid 41672353)
5. Weisberg HI, Hayden VC, Pontes VP,. Selection criteria and generalizability within the counterfactual framework: explaining the paradox of antidepressant-induced suicidality? Clin Trials 2009; 6: 109-118.
6. Dzewaltowski DA, Estabrooks PA, Klesges LM, et al. Behavior change intervention research in community settings: how generalizable are the results? Health Promot Int 2004; 19: 235-245. (Pubitemid 38724515)
7. Gaynes BN, Warden D, Trivedi MH, et al. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 2009; 60: 1439-1445.
8. Blanco C, Olfson M, Goodwin RD, et al. Generalizability of clinical trial results for major depression to community samples: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2008; 69: 1276-1280.
9. Zimmerman M, Chelminski I, Posternak MA,. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry 2005; 162: 1370-1372. (Pubitemid 40905589)
10. Zimmerman M, Mattia JI, Posternak MA,. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 2002; 159: 469-473. (Pubitemid 34184745)
11. Boter H, Derks EM, Fleischhacker WW, et al. Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry 71: 58-65.
12. Leucht S, Heres S, Hamann J, Kane JM,. Methodological issues in current antipsychotic drug trials. Schizophr Bull 2008; 34: 275-285. (Pubitemid 351323339)
13. Khan AY, Preskorn SH, Baker B,. Effect of study criteria on recruitment and generalizability of the results. J Clin Psychopharmacol 2005; 25: 271-275. (Pubitemid 40685794)
14. Blanco C, Olfson M, Okuda M, et al. Generalizability of clinical trials for alcohol dependence to community samples. Drug Alcohol Depend 2008; 98: 123-128.
15. Humphreys K, Weingardt KR, Harris AH,. Influence of subject eligibility criteria on compliance with National Institutes of Health guidelines for inclusion of women, minorities, and children in treatment research. Alcohol Clin Exp Res 2007; 31: 988-995. (Pubitemid 46776177)
16. Humphreys K, Weingardt KR, Horst D, et al. Prevalence and predictors of research participant eligibility criteria in alcohol treatment outcome studies, 1970-98. Addiction 2005; 100: 1249-1257. (Pubitemid 41248066)
17. Okuda M, Hasin DS, Olfson M, et al. Generalizability of clinical trials for cannabis dependence to community samples. Drug Alcohol Depend 111: 177-181.
18. Le Strat Y, Rehm J, Le Foll B,. How generalisable to community samples are clinical trial results for treatment of nicotine dependence: a comparison of common eligibility criteria with respondents of a large representative general population survey. Tob Control 2011; 20: 338-343.
19. Baldwin D, Woods R, Lawson R, Taylor D,. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ 342: d1199.
20. Mitte K,. Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy. Psychol Bull 2005; 131: 785-795. (Pubitemid 41463587)
21. Westen D, Morrison K,. A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: an empirical examination of the status of empirically supported therapies. J Consult Clin Psychol 2001; 69: 875-899. (Pubitemid 33140488)
22. March JS, Silva SG, Compton S, et al. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005; 162: 836-846. (Pubitemid 40676194)
23. Wells KB,. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry 1999; 156: 5-10. (Pubitemid 29034873)
24. Grant BF, Dawson DA, Stinson FS, et al. The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV): reliability of alcohol consumption, tobacco use, family history of depression and psychiatric diagnostic modules in a general population sample. Drug Alcohol Depend 2003; 71: 7-16. (Pubitemid 36734856)
25. Grant BF, Dawson DA, Stinson FS, et al. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend 2004; 74: 223-234. (Pubitemid 38759777)
26. Grant BF, Harford TC, Dawson DA, et al. The Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): reliability of alcohol and drug modules in a general population sample. Drug Alcohol Depend 1995; 39: 37-44.
27. Hasin D, Carpenter KM, McCloud S, et al. The alcohol use disorder and associated disabilities interview schedule (AUDADIS): reliability of alcohol and drug modules in a clinical sample. Drug Alcohol Depend 1997; 44: 133-141. (Pubitemid 27129506)
28. Canino G, Bravo M, Ramirez R, et al. The Spanish Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): reliability and concordance with clinical diagnoses in a Hispanic population. J Stud Alcohol 1999; 60: 790-799. (Pubitemid 29526544)
29. Hasin DS, Stinson FS, Ogburn E, Grant BF,. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2007; 64: 830-842. (Pubitemid 47026379)
30. Nicolini H, Bakish D, Duenas H, et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med 2009; 39: 267-276.
31. Pollack MH, Tiller J, Xie F, Trivedi MH,. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol 2008; 28: 308-316.
32. Rynn M, Russell J, Erickson J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 2008; 25: 182-189. (Pubitemid 351499896)
33. Brawman-Mintzer O, Knapp RG, Rynn M, et al. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006; 67: 874-881. (Pubitemid 44049085)
34. Montgomery SA, Tobias K, Zornberg GL, et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006; 67: 771-782. (Pubitemid 43946184)
35. Wan GJ, Zhang HF, Tedeschi MA, Hackett D,. Estimation of symptom-free days in generalized anxiety disorder. Curr Med Res Opin 2006; 22: 587-591.
36. Pollack MH, Roy-Byrne PP, Van Ameringen M, et al. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry 2005; 66: 1401-1408. (Pubitemid 41779538)
37. Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005; 62: 1022-1030. (Pubitemid 41248382)
38. Ball SG, Kuhn A, Wall D, et al. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry 2005; 66: 94-99.
39. Steiner M, Allgulander C, Ravindran A, et al. Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder. Hum Psychopharmacol 2005; 20: 3-13. (Pubitemid 40227640)
40. Nimatoudis I, Zissis NP, Kogeorgos J, et al. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. Int Clin Psychopharmacol 2004; 19: 331-336. (Pubitemid 39506987)
41. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23: 240-249. (Pubitemid 36807791)
42. Rickels K, Zaninelli R, McCafferty J, et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160: 749-756. (Pubitemid 41079609)
43. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003; 160: 533-540. (Pubitemid 41094262)
44. Silverstone PH, Salinas E,. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 2001; 62: 523-529. (Pubitemid 32703091)
45. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62: 350-357. (Pubitemid 32545557)
46. Davidson JR, DuPont RL, Hedges D, Haskins JT,. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999; 60: 528-535. (Pubitemid 29413473)
47. Hartford JT, Endicott J, Kornstein SG, et al. Implications of pain in generalized anxiety disorder: efficacy of duloxetine. Prim Care Companion J Clin Psychiatry 2008; 10: 197-204. (Pubitemid 351879954)
48. Koponen H, Allgulander C, Erickson J, et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry 2007; 9: 100-107. (Pubitemid 46607463)
49. Davidson JR, Bose A, Korotzer A, Zheng H,. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 2004; 19: 234-240. (Pubitemid 39014143)
50. Baldwin DS, Huusom AK, Maehlum E,. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Brit J Psychiatry 2006; 189: 264-272. (Pubitemid 44343473)
51. Montgomery S, Chatamra K, Pauer L, et al. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Brit J Psychiatry 2008; 193: 389-394.
52. Lenox-Smith AJ, Reynolds A,. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Brit J Gen Pract 2003; 53: 772-777. (Pubitemid 37254121)
53. Hartford J, Kornstein S, Liebowitz M, et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007; 22: 167-174. (Pubitemid 46559873)
54. Blowers C, Cobb J, Mathews A,. Generalised anxiety: a controlled treatment study. Behav Res Ther 1987; 25: 493-502. (Pubitemid 17163884)
55. Borkovec TD, Costello E,. Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol 1993; 61: 611-619. (Pubitemid 23230083)
56. Butler G, Fennell M, Robson P, Gelder M,. Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol 1991; 59: 167-175.
57. Ladouceur R, Dugas MJ, Freeston MH, et al. Efficacy of a cognitive-behavioral treatment for generalized anxiety disorder: evaluation in a controlled clinical trial. J Consult Clin Psychol 2000; 68: 957-964. (Pubitemid 32038374)
58. Woodward R, Jones RB,. Cognitive restructuring treatment: a controlled trail with anxious patients. Behav Res Ther 1980; 18: 401-407. (Pubitemid 11209034)
59. Barlow D, Cohen AS, Waddell MT, et al. Panic and generalized anxiety disorder: nature and treatment. Behav Therapy 1984; 15: 431-449. (Pubitemid 15175425)
60. Butler G, Cullington A, Hibbert G, Klimes I, Gelder M,. Anxiety management for persistent generalised anxiety. Brit J Psychiatry 1987; 151: 535-542. (Pubitemid 17155551)
61. Cragan M, Deffenbacher JL,. Anxiety management training and relaxation as self-control in the treatment of generalized anxiety in medical outpatients. J Counsel Psychol 1984; 31: 123-131.
62. Jannoun L, Oppenheimer C, Gelder M,. A self-help treatment program for anxiety state patients. Behav Therapy 1982; 13: 103-111. (Pubitemid 12169620)
63. Power K, Simpson RJ, Swanson V, Wallace LA,. A controlled comparison of cognitive-behaviour therapy, diazepam, and placebo, alone and in combination, for the treatment of generalised anxiety disorder. J Anxiety Disord 1990; 4: 267-292.
64. Bowman D, Scogin F, Floyd M, Patton E, Gist L,. Efficacy of self-examination therapy in the treatment of generalized anxiety disorder. J Counsel Psychol 1997; 44: 267-273. (Pubitemid 127465996)
65. Barlow D, Rapee RM, Brown TA,. Behavioral treatment of generalized anxiety disorder. Behav Therapy 1992; 23: 551-570.
66. Cohen P, Cohen J,. The clinician's illusion. Arch Gen Psychiatry 1984; 41: 1178-1182. (Pubitemid 15215485)
67. Kirchner JE, Booth BM, Owen RR, et al. Predictors of patient entry into alcohol treatment after initial diagnosis. J Behav Health Serv Res 2000; 27: 339-346. (Pubitemid 30485801)
68. Hettema JM,. The nosologic relationship between generalized anxiety disorder and major depression. Depress Anxiety 2008; 25: 300-316. (Pubitemid 351614565)
69. Adam Y, Meinlschmidt G, Gloster AT, Lieb R,. Obsessive-compulsive disorder in the community: 12-month prevalence, comorbidity and impairment. Soc Psychiatry Psychiatr Epidemiol 2012; 3: 339-349.
70. Ruscio AM, Stein DJ, Chiu WT, Kessler RC,. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 15: 53-63.
71. Olfson M, Marcus SC,. National trends in outpatient psychotherapy. Am J Psychiatry 167: 1456-1463.
72. Verdoux H, Begaud B,. Pharmaco-epidemiology: what do (and don't) we know about utilisation and impact of psychotropic medications in real-life conditions? Brit J Psychiatry 2004; 185: 93-94. (Pubitemid 39061449)